Medical Outcomes

This site is intended for healthcare professionals. Product licences differ between countries. Please consult your local prescribing information.

Welcome to Medical Outcomes

Medical Outcomes a department within Pfizer Endocrine Care Medical Worldwide, provides databases (KIGS, KIMS and ACROSTUDY) and standardized procedures for collection of pharmacoepidemiological data on patients receiving Genotropin®/Genotonorm® (somatropin [rDNA origin] for injection) or Somavert® (pegvisomant for injection) through established prescribing practices.

KIGS, KIMS and ACROSTUDY are important tools within modern evidence based medicine and support physicians in optimizing the treatment of individual patients as well as contribute to a wider understanding of growth hormone and Somavert® treatment.

KIGS, KIMS and ACROSTUDY are managed by Strategic Advisory Boards, whose members are elected from the pool of participating physicians. Data are regularly analyzed and the results published in peer-reviewed medical journals and reports.                      

About KIGS

Pfizer International Growth Database
-includes data on children and adolescents with growth disorders treated with Genotropin®/Genotonorm®.

If you have any questions regarding KIGS, please contact Ferah Aydin,
KIGS Manager

About KIMS

Pfizer International Metabolic Database
-includes data on adult patients with growth hormone deficiency (GHD)

If you have any questions regarding KIMS, please contact Ann-Charlotte ÅkerbladKIMS Manager

About ACROSTUDY

Pfizer International Somavert® Database
-includes data on patients with acromegaly
receiving Somavert
®

If you have any questions regarding ACROSTUDY, please contact Ann-Charlotte Åkerblad ACROSTUDY Manager